The purpose of the trial is to see which of these treatments most effectively clears the bacteria from the lungs, a result known as microbiological eradication. Participants are randomly assigned to receive one of the three options for a short treatment period, then they return for regular check‑ups where sputum samples are collected and health questionnaires are completed to monitor safety, symptom changes, and overall well‑being.

Follow‑up continues for several months after the medication stops, allowing researchers to observe whether the infection stays cleared, how often lung flare‑ups occur, and any side effects that may appear. The information gathered will help determine the best approach to manage this bacterial infection in people with bronchiectasis.

The purpose of the study is to evaluate how well GSK3862995B works compared with placebo in people with bronchiectasis. The study will look at whether the medication can reduce the number of times patients experience flare-ups of their condition over time. The study will also examine the safety of the medication, how the body’s immune system responds to it, and how the medication moves through and is processed by the body.

During this study, participants will receive repeated doses of either GSK3862995B or placebo over a period of time. The study is designed so that neither the participants nor the doctors will know who is receiving the actual medication and who is receiving the placebo until the study is completed. Throughout the study, doctors will monitor how often participants experience flare-ups of their bronchiectasis, how long it takes before the first flare-up occurs, and how many severe flare-ups happen. The study is expected to continue until late 2027.

During the trial, participants are assigned to receive either AZD0292 or a placebo. The study is double-blind, meaning that neither the participants nor the researchers know which treatment is being administered until the study is finished. The research will monitor how the medication moves through the body, a process known as pharmacokinetics, and track any pulmonary exacerbations, which are sudden increases in symptoms like coughing or shortness of breath. Participants will be monitored over a period of time to observe how the treatment affects the frequency of these lung symptom flare-ups.

The purpose of the study is to find out if giving azithromycin for six months can reduce the number of times children with these lung problems experience respiratory infections that get worse and need treatment. During the study, children will receive either azithromycin or placebo by mouth for a period of six months. The medicine comes as a liquid suspension that can be swallowed. Researchers will track how many times the children develop breathing problems that get worse during the treatment period, which are called respiratory exacerbations.

The study will also look at other important information such as how long these episodes of worsening breathing problems last, how many times children need to be admitted to the hospital, and how long those hospital stays are. Children participating in the study will be between zero and seventy-two months of age, which means from newborns up to six years old. All participating children will already be receiving care at specialized pediatric lung centers.

The purpose of this research is to evaluate how well CSL787 works in preventing flare-ups of the disease and to determine the most effective dose. The medication will be given through a nebulizer, which is a device that turns liquid medicine into a fine mist that can be inhaled into the lungs. The study will last for up to 12 months.

During the study, participants will be randomly assigned to receive either different doses of CSL787 or a placebo through the nebulizer. The study will monitor how long it takes before participants experience their first disease flare-up and will also track other aspects of their lung health and overall well-being. This is a double-blind study, which means neither the participants nor the doctors conducting the study will know who is receiving which treatment.

The study medication comes in the form of film-coated tablets that are taken by mouth once daily. The treatment period lasts up to 76 weeks, during which participants will receive either BI 1291583 at a dose of 2.5 mg or a matching placebo. This is part of what is called a Phase III study, which is one of the final stages of testing a new medication before it can be approved for general use.

Throughout the study, participants will be monitored for improvements in their condition, particularly focusing on how often they experience pulmonary exacerbations (sudden worsening of respiratory symptoms that require antibiotic treatment). The study will also track changes in breathing tests and how the treatment affects participants’ quality of life related to their respiratory symptoms.

The purpose of the study is to evaluate how well Ensifentrine works in reducing lung flare-ups in people with Non-Cystic Fibrosis Bronchiectasis. Participants will be randomly assigned to receive either Ensifentrine or a placebo. The study will be conducted in a way that neither the participants nor the researchers know who is receiving the actual treatment or the placebo, ensuring unbiased results. The treatment will be administered twice a day using a nebulizer, a device that turns liquid medicine into a mist for inhalation.

Throughout the study, participants will attend regular visits to monitor their health and the effects of the treatment. The study will last for several months, during which the frequency of lung flare-ups and other health indicators will be closely observed. This research aims to provide valuable information on the potential benefits of Ensifentrine for individuals with Non-Cystic Fibrosis Bronchiectasis.

The purpose of the study is to evaluate the effect of ColiFin® therapy compared to standard care in achieving negative sputum or airway cultures for Pseudomonas aeruginosa 28 weeks after starting the treatment. Participants in the study will be randomly assigned to receive either the ColiFin® treatment or standard care. The study will monitor the participants over a period of 28 weeks to observe changes in their condition, including the presence of the bacteria in their sputum, the occurrence of lung flare-ups, and any changes in their quality of life and respiratory symptoms.

Throughout the study, researchers will collect data on various aspects, such as the rate of lung exacerbations, which are episodes where symptoms suddenly worsen, and any changes in the participants’ ability to fight off the bacteria. The study aims to provide insights into whether ColiFin® can effectively help manage bronchiectasis in patients with this specific bacterial infection.

The purpose of the study is to evaluate how effective this combination of inhaling the hypertonic saline solution once a day and performing the ELTGOL technique twice a day is in helping patients clear mucus from their lungs. The study will compare this treatment to two other approaches: inhaling a less concentrated saltwater solution, known as isotonic saline, once a day along with the ELTGOL technique twice a day, and performing the ELTGOL technique on its own twice a day.

Participants in the study will follow one of these treatment plans over a period of 12 months. Throughout the study, changes in the amount and characteristics of mucus, the frequency of lung infections, and the overall quality of life will be monitored. The study aims to provide insights into the best approach for managing mucus clearance in patients with bronchiectasis, potentially improving their respiratory health and quality of life.

The purpose of the study is to determine if the first treatment option is not worse than the second in terms of clearing the PA infection over a period of 6 months. Participants will be monitored for 6 months to see if the PA infection is eradicated. The study will also look at other factors such as the time it takes for any worsening of symptoms, the quality of life of participants, and how burdensome the treatment is. Additionally, the study will assess the recurrence of PA and the bacteria’s resistance to ciprofloxacin over time.

Participants will be asked to take part in regular follow-up visits to monitor their health and the effectiveness of the treatment. They will also complete questionnaires to help assess their quality of life and the impact of the treatment. The study aims to provide valuable information on the best way to treat early PA infections in people with bronchiectasis, potentially improving treatment strategies and patient outcomes in the future.

The purpose of the study is to evaluate how safe and tolerable these new treatments are for patients with this lung condition. Participants will use the nebulizer to inhale the treatment, and some may receive a placebo for comparison. The study will also involve the use of a common medication called salbutamol sulfate, which is often used to help open the airways in the lungs. This medication is delivered using an inhaler. Throughout the study, participants will be monitored for any side effects and changes in their health, including vital signs like blood pressure and heart rate.

The trial will take place over a period of time, during which participants will be asked to attend several study visits. During these visits, they will undergo various assessments to check their health and the effects of the treatment. The study aims to gather important information that could help improve the treatment of Non-Cystic Fibrosis Bronchiectasis in the future.

The purpose of the study is to evaluate how effective itepekimab is compared to a placebo in reducing lung flare-ups, known as pulmonary exacerbations, in people with non-cystic fibrosis bronchiectasis. Participants in the study will receive either itepekimab or a placebo through an injection under the skin. The study will monitor participants over a period to see how often these lung flare-ups occur and to assess the safety and tolerability of the treatment.

Throughout the study, various aspects will be observed, such as the time it takes for the first lung flare-up to occur, the number of participants who remain free from these flare-ups, and any changes in lung function. The study will also look at the quality of life related to respiratory symptoms and any side effects that may arise from the treatment. The goal is to gather information that could help improve the management of non-cystic fibrosis bronchiectasis in the future.

The purpose of the study is to determine if patients with chronic bronchial infection, after receiving a course of targeted oral or intravenous treatment, experience a reduction in bacterial growth when treated with inhaled antibiotics. Participants will receive treatment over a period of 48 weeks. During this time, they will be monitored to assess the impact of the inhaled antibiotics on their lung health.

Participants in the study will be adults aged 20 to 90 years who have been diagnosed with bronchiectasis and have had at least two positive sputum cultures for the same germ in the past year. The study will help understand if inhaled antibiotics can be an effective strategy for managing chronic bronchial infections in people with bronchiectasis.

Participants in the study will receive either Gremubamab or a placebo, which is a substance with no active medication, through an intravenous infusion, meaning it is administered directly into the vein. The study will last for a total of 12 weeks, during which participants will have regular check-ups to monitor their health and the effects of the treatment. The main goal is to see if Gremubamab can help reduce the bacterial burden in the lungs, potentially leading to fewer infections and improved lung function.

The trial is designed to gather important information about the potential benefits of Gremubamab for people with bronchiectasis and chronic Pseudomonas aeruginosa infection. By participating in this study, researchers hope to find a new way to manage this challenging condition and improve the quality of life for those affected. The study will follow a structured schedule, with assessments at various points to track progress and gather data on the treatment’s effectiveness.

The purpose of the study is to see how well BI 1291583 is tolerated by people with cystic fibrosis bronchiectasis. Participants will take the medication or placebo for 12 weeks. During this time, researchers will monitor the participants to see if they experience any side effects and how their bodies process the medication. The study will also involve the use of salbutamol sulfate, a common medication used to help open the airways in the lungs, which will be administered through inhalation.

Throughout the study, participants will have regular check-ups to ensure their safety and to gather information on how the treatment is working. The trial aims to provide valuable insights into the safety and effectiveness of BI 1291583 for treating cystic fibrosis bronchiectasis, potentially leading to better treatment options for those affected by this condition.

Participants in this study will receive either the medication BI 1291583 or a placebo, which looks like the medication but does not contain the active ingredient. The purpose of the study is to evaluate the safety of the medication by monitoring any side effects that occur during the trial. The study will also look at how the medication affects the time it takes for a lung flare-up, known as a pulmonary exacerbation, to occur and how often these flare-ups happen.

The study will last for up to 12 months, during which participants will take the medication daily. The trial is designed to be a roll-over study, meaning it includes people who have already participated in a previous study with BI 1291583. This approach helps researchers understand the long-term effects of the medication in a real-world setting. Participants will be closely monitored throughout the study to ensure their safety and to gather data on the medication’s impact on their condition.